stockrow
Friday 6 November 2026
Export GH’s income statement to Excel — free account
Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
150.48
2.95
−1.92%
Follow GH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
18.75 | 16.85 | 11.23 | 13.04 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1,011.33) | (345.01) | (184.78) | (485.56) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
19.10 | 17.23 | 11.60 | 13.35 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(140.79) | (110.07) | (66.74) | (70.95) | |
EV/FCF |
(97.68) | (78.82) | (49.12) | (52.23) | |
Quick Ratio |
0.50 | 3.53 | 4.25 | 4.42 | |
Current Ratio |
3.60 | 4.03 | 4.68 | 4.84 | |
Net Debt/EBITDA |
0.00 | (3.73) | (3.37) | (2.59) | |
Debt/Assets |
79.68% | 78.59% | 78.50% | 74.69% | |
Debt/Equity |
(5.45) | (6.74) | (8.30) | (15.14) | |
Asset Turnover |
0.81 | 0.73 | 0.66 | 0.56 | |
Operating CF/Net income |
0.19 | 0.48 | 0.59 | 0.21 | |
Capex/Depreciation |
0.00 | (1.37) | (2.27) | (6.67) | |
Interest Coverage |
(98.71) | (95.93) | (90.09) | (102.38) | |
Research and Development Expense of Revenue |
27.93% | 28.82% | 30.18% | 34.94% | |
Selling, General and Administrative Expense of Revenue |
74.27% | 75.11% | 75.27% | 72.64% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
17.30% | 17.23% | 15.78% | 15.36% | |
Graham Net Nets |
(0.03) | (0.04) | (0.06) | (0.05) | |
Graham Number |
13.04 | 11.48 | 10.26 | 7.68 | |
Earnings Yield |
(2.06%) | (2.33%) | (3.67%) | (3.24%) | |
Free Cash Flow Yield |
(1.04%) | (1.30%) | (2.10%) | (1.96%) | |
Revenue per Share |
2.69 | 2.52 | 2.30 | 2.24 | |
Operating CF per Share |
(0.18) | (0.43) | (0.50) | (0.21) | |
Capex per Share |
(0.10) | (0.09) | (0.04) | (0.22) | |
Free Cash Flow per Share |
(0.28) | (0.52) | (0.54) | (0.43) | |
Cash per Share |
0.00 | 7.93 | 8.40 | 9.58 | |
Shareholders Equity per Share |
(2.05) | (1.68) | (1.38) | (0.79) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.05) | (1.68) | (1.38) | (0.79) | |
Free Cash Flow |
(37.19) | (69.54) | (71.20) | (54.22) | |
Working Capital |
970.24 | 1,025.68 | 1,075.36 | 1,163.32 | |
Capital Expenditures |
(13.48) | (11.76) | (5.58) | (27.85) | |
Net Current Asset Value |
(818.14) | (770.52) | (728.86) | (646.92) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.04 | 0.02 | 0.10 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
151.07 | 137.25 | 126.42 | 124.05 | |
Average Payables |
61.33 | 69.16 | 62.40 | 46.50 | |
Average Inventory |
91.99 | 94.76 | 80.55 | 78.48 | |
Average Assets |
1,581.21 | 1,622.15 | 1,629.76 | 1,749.63 | |
Average Common Equity |
(315.19) | (264.17) | (215.93) | (119.48) |
Columns are period end dates · fundamentals updated 5 Nov 2026